Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. In a release it put out late Tuesday ...

Medical genetics company Invitae released a first-of-its-kind data use transparency and impact report today detailing the impact of patient data on genetic research. The report comes as concerns about ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

San Francisco-based genetic diagnostics company Invitae has acquired Good Start Genetics and CombiMatrix, expanding Invitae’s portfolio to include prenatal and pediatric testing. It’s part of their ...

Invitae is boosting its neurology and cardiology diagnostic test offerings. The San Francisco-based company will be adding 11 panels for heritable diseases and will update 17 existing neurology panels ...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...

Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...